nodes	percent_of_prediction	percent_of_DWPC	metapath
Ketamine—CYP2B6—Efavirenz—acquired immunodeficiency syndrome	0.0438	0.0577	CbGbCtD
Ketamine—CYP2B6—Lopinavir—acquired immunodeficiency syndrome	0.0411	0.0542	CbGbCtD
Ketamine—CYP2B6—Nevirapine—acquired immunodeficiency syndrome	0.0411	0.0542	CbGbCtD
Ketamine—CYP2B6—Amprenavir—acquired immunodeficiency syndrome	0.0372	0.0491	CbGbCtD
Ketamine—CYP2B6—Nelfinavir—acquired immunodeficiency syndrome	0.0312	0.0411	CbGbCtD
Ketamine—CYP2B6—Ritonavir—acquired immunodeficiency syndrome	0.0282	0.0372	CbGbCtD
Ketamine—CYP2C8—Amprenavir—acquired immunodeficiency syndrome	0.0282	0.0372	CbGbCtD
Ketamine—CYP2C8—Delavirdine—acquired immunodeficiency syndrome	0.0282	0.0372	CbGbCtD
Ketamine—CYP2C9—Efavirenz—acquired immunodeficiency syndrome	0.0231	0.0305	CbGbCtD
Ketamine—CYP2C9—Nevirapine—acquired immunodeficiency syndrome	0.0217	0.0287	CbGbCtD
Ketamine—CYP2C9—Lopinavir—acquired immunodeficiency syndrome	0.0217	0.0287	CbGbCtD
Ketamine—CYP2C8—Saquinavir—acquired immunodeficiency syndrome	0.0214	0.0282	CbGbCtD
Ketamine—CYP2C8—Ritonavir—acquired immunodeficiency syndrome	0.0214	0.0282	CbGbCtD
Ketamine—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.0211	0.0278	CbGbCtD
Ketamine—CYP2C8—Zidovudine—acquired immunodeficiency syndrome	0.0205	0.027	CbGbCtD
Ketamine—CYP2C9—Delavirdine—acquired immunodeficiency syndrome	0.0197	0.0259	CbGbCtD
Ketamine—CYP2C9—Amprenavir—acquired immunodeficiency syndrome	0.0197	0.0259	CbGbCtD
Ketamine—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.0191	0.0251	CbGbCtD
Ketamine—CYP2C9—Indinavir—acquired immunodeficiency syndrome	0.017	0.0224	CbGbCtD
Ketamine—CYP2C9—Nelfinavir—acquired immunodeficiency syndrome	0.0165	0.0217	CbGbCtD
Ketamine—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.0165	0.0217	CbGbCtD
Ketamine—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.016	0.0211	CbGbCtD
Ketamine—CYP2C9—Ritonavir—acquired immunodeficiency syndrome	0.0149	0.0196	CbGbCtD
Ketamine—CYP2C9—Saquinavir—acquired immunodeficiency syndrome	0.0149	0.0196	CbGbCtD
Ketamine—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.0145	0.0191	CbGbCtD
Ketamine—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.0145	0.0191	CbGbCtD
Ketamine—CYP2C9—Zidovudine—acquired immunodeficiency syndrome	0.0143	0.0188	CbGbCtD
Ketamine—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.0139	0.0183	CbGbCtD
Ketamine—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.0134	0.0177	CbGbCtD
Ketamine—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.0126	0.0167	CbGbCtD
Ketamine—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.0126	0.0167	CbGbCtD
Ketamine—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.0114	0.0151	CbGbCtD
Ketamine—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.0114	0.0151	CbGbCtD
Ketamine—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.0107	0.0141	CbGbCtD
Ketamine—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00987	0.013	CbGbCtD
Ketamine—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00958	0.0126	CbGbCtD
Ketamine—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00866	0.0114	CbGbCtD
Ketamine—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00866	0.0114	CbGbCtD
Ketamine—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.0083	0.0109	CbGbCtD
Ketamine—GRIN2C—nerve—acquired immunodeficiency syndrome	0.00595	0.0658	CbGeAlD
Ketamine—GRIN2B—nerve—acquired immunodeficiency syndrome	0.0047	0.052	CbGeAlD
Ketamine—TACR1—nerve—acquired immunodeficiency syndrome	0.00451	0.0498	CbGeAlD
Ketamine—GRIN2A—nerve—acquired immunodeficiency syndrome	0.00411	0.0454	CbGeAlD
Ketamine—GRIN3B—lung—acquired immunodeficiency syndrome	0.00301	0.0332	CbGeAlD
Ketamine—OPRM1—nerve—acquired immunodeficiency syndrome	0.0025	0.0276	CbGeAlD
Ketamine—Nystagmus—Delavirdine—acquired immunodeficiency syndrome	0.0022	0.0231	CcSEcCtD
Ketamine—Laryngospasm—Delavirdine—acquired immunodeficiency syndrome	0.0021	0.0221	CcSEcCtD
Ketamine—Apnoea—Efavirenz—acquired immunodeficiency syndrome	0.00193	0.0204	CcSEcCtD
Ketamine—Muscle twitching—Zidovudine—acquired immunodeficiency syndrome	0.0019	0.02	CcSEcCtD
Ketamine—SLC6A2—nerve—acquired immunodeficiency syndrome	0.00183	0.0202	CbGeAlD
Ketamine—Cystitis noninfective—Zidovudine—acquired immunodeficiency syndrome	0.00182	0.0192	CcSEcCtD
Ketamine—Cystitis—Zidovudine—acquired immunodeficiency syndrome	0.0018	0.019	CcSEcCtD
Ketamine—Bladder pain—Zidovudine—acquired immunodeficiency syndrome	0.00169	0.0178	CcSEcCtD
Ketamine—DRD2—nerve—acquired immunodeficiency syndrome	0.00167	0.0184	CbGeAlD
Ketamine—Salivary hypersecretion—Delavirdine—acquired immunodeficiency syndrome	0.00152	0.016	CcSEcCtD
Ketamine—Muscle twitching—Ritonavir—acquired immunodeficiency syndrome	0.00148	0.0156	CcSEcCtD
Ketamine—GRIN2D—spinal cord—acquired immunodeficiency syndrome	0.00148	0.0163	CbGeAlD
Ketamine—Cystitis noninfective—Ritonavir—acquired immunodeficiency syndrome	0.00142	0.0149	CcSEcCtD
Ketamine—Cystitis—Ritonavir—acquired immunodeficiency syndrome	0.0014	0.0148	CcSEcCtD
Ketamine—Muscle twitching—Lamivudine—acquired immunodeficiency syndrome	0.00136	0.0143	CcSEcCtD
Ketamine—GRIN2C—nervous system—acquired immunodeficiency syndrome	0.00134	0.0148	CbGeAlD
Ketamine—GRIN1—spinal cord—acquired immunodeficiency syndrome	0.00132	0.0145	CbGeAlD
Ketamine—Bladder pain—Ritonavir—acquired immunodeficiency syndrome	0.00131	0.0138	CcSEcCtD
Ketamine—TACR1—digestive system—acquired immunodeficiency syndrome	0.00131	0.0145	CbGeAlD
Ketamine—GRIN2C—central nervous system—acquired immunodeficiency syndrome	0.00129	0.0142	CbGeAlD
Ketamine—GRIN2B—spinal cord—acquired immunodeficiency syndrome	0.00125	0.0139	CbGeAlD
Ketamine—TACR1—blood—acquired immunodeficiency syndrome	0.00125	0.0138	CbGeAlD
Ketamine—GRIN2D—nervous system—acquired immunodeficiency syndrome	0.00124	0.0137	CbGeAlD
Ketamine—TACR1—spinal cord—acquired immunodeficiency syndrome	0.0012	0.0133	CbGeAlD
Ketamine—GRIN2D—central nervous system—acquired immunodeficiency syndrome	0.0012	0.0132	CbGeAlD
Ketamine—Diplopia—Efavirenz—acquired immunodeficiency syndrome	0.00119	0.0125	CcSEcCtD
Ketamine—GRIN3A—nervous system—acquired immunodeficiency syndrome	0.00117	0.0129	CbGeAlD
Ketamine—Diplopia—Delavirdine—acquired immunodeficiency syndrome	0.00114	0.012	CcSEcCtD
Ketamine—CYP2C8—blood plasma—acquired immunodeficiency syndrome	0.00114	0.0126	CbGeAlD
Ketamine—GRIN3A—central nervous system—acquired immunodeficiency syndrome	0.00113	0.0124	CbGeAlD
Ketamine—GRIN1—nervous system—acquired immunodeficiency syndrome	0.00111	0.0123	CbGeAlD
Ketamine—GRIN2A—spinal cord—acquired immunodeficiency syndrome	0.0011	0.0121	CbGeAlD
Ketamine—TACR1—lung—acquired immunodeficiency syndrome	0.00109	0.0121	CbGeAlD
Ketamine—GRIN1—central nervous system—acquired immunodeficiency syndrome	0.00107	0.0118	CbGeAlD
Ketamine—GRIN2B—nervous system—acquired immunodeficiency syndrome	0.00106	0.0117	CbGeAlD
Ketamine—GRIN2A—vagina—acquired immunodeficiency syndrome	0.00106	0.0117	CbGeAlD
Ketamine—Diplopia—Ritonavir—acquired immunodeficiency syndrome	0.00105	0.0111	CcSEcCtD
Ketamine—PTGS1—endothelium—acquired immunodeficiency syndrome	0.00104	0.0115	CbGeAlD
Ketamine—GRIN2C—brain—acquired immunodeficiency syndrome	0.00102	0.0113	CbGeAlD
Ketamine—CYP2B6—blood plasma—acquired immunodeficiency syndrome	0.00102	0.0113	CbGeAlD
Ketamine—GRIN2B—central nervous system—acquired immunodeficiency syndrome	0.00102	0.0113	CbGeAlD
Ketamine—TACR1—nervous system—acquired immunodeficiency syndrome	0.00101	0.0112	CbGeAlD
Ketamine—CYP2C9—blood plasma—acquired immunodeficiency syndrome	0.00101	0.0112	CbGeAlD
Ketamine—TACR1—central nervous system—acquired immunodeficiency syndrome	0.000976	0.0108	CbGeAlD
Ketamine—Erythema—Nevirapine—acquired immunodeficiency syndrome	0.000972	0.0102	CcSEcCtD
Ketamine—GRIN2D—brain—acquired immunodeficiency syndrome	0.00095	0.0105	CbGeAlD
Ketamine—Erythema—Nelfinavir—acquired immunodeficiency syndrome	0.000941	0.00991	CcSEcCtD
Ketamine—GRIN2A—nervous system—acquired immunodeficiency syndrome	0.000924	0.0102	CbGeAlD
Ketamine—Anorexia—Amprenavir—acquired immunodeficiency syndrome	0.000923	0.00971	CcSEcCtD
Ketamine—PTGS1—blood plasma—acquired immunodeficiency syndrome	0.000921	0.0102	CbGeAlD
Ketamine—GRIN3A—brain—acquired immunodeficiency syndrome	0.000893	0.00988	CbGeAlD
Ketamine—GRIN2A—central nervous system—acquired immunodeficiency syndrome	0.00089	0.00984	CbGeAlD
Ketamine—Anaphylactic shock—Didanosine—acquired immunodeficiency syndrome	0.000882	0.00929	CcSEcCtD
Ketamine—GRIN1—brain—acquired immunodeficiency syndrome	0.000847	0.00937	CbGeAlD
Ketamine—Decreased appetite—Amprenavir—acquired immunodeficiency syndrome	0.000841	0.00886	CcSEcCtD
Ketamine—Anorexia—Didanosine—acquired immunodeficiency syndrome	0.000841	0.00886	CcSEcCtD
Ketamine—OPRD1—nervous system—acquired immunodeficiency syndrome	0.000824	0.00911	CbGeAlD
Ketamine—Erythema—Zidovudine—acquired immunodeficiency syndrome	0.000816	0.00859	CcSEcCtD
Ketamine—Convulsion—Nelfinavir—acquired immunodeficiency syndrome	0.000816	0.00859	CcSEcCtD
Ketamine—GRIN2B—brain—acquired immunodeficiency syndrome	0.000808	0.00894	CbGeAlD
Ketamine—Bradycardia—Delavirdine—acquired immunodeficiency syndrome	0.000802	0.00845	CcSEcCtD
Ketamine—Convulsion—Abacavir—acquired immunodeficiency syndrome	0.000801	0.00844	CcSEcCtD
Ketamine—Anaphylactic shock—Nevirapine—acquired immunodeficiency syndrome	0.000793	0.00835	CcSEcCtD
Ketamine—OPRD1—central nervous system—acquired immunodeficiency syndrome	0.000793	0.00877	CbGeAlD
Ketamine—OPRK1—nervous system—acquired immunodeficiency syndrome	0.00079	0.00873	CbGeAlD
Ketamine—TACR1—brain—acquired immunodeficiency syndrome	0.000775	0.00857	CbGeAlD
Ketamine—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000769	0.00851	CbGeAlD
Ketamine—Decreased appetite—Didanosine—acquired immunodeficiency syndrome	0.000767	0.00808	CcSEcCtD
Ketamine—OPRK1—central nervous system—acquired immunodeficiency syndrome	0.00076	0.00841	CbGeAlD
Ketamine—Anorexia—Nevirapine—acquired immunodeficiency syndrome	0.000756	0.00796	CcSEcCtD
Ketamine—Anaphylactic shock—Abacavir—acquired immunodeficiency syndrome	0.000755	0.00795	CcSEcCtD
Ketamine—Pain—Didanosine—acquired immunodeficiency syndrome	0.000754	0.00794	CcSEcCtD
Ketamine—TACR1—lymph node—acquired immunodeficiency syndrome	0.000749	0.00828	CbGeAlD
Ketamine—Arrhythmia—Efavirenz—acquired immunodeficiency syndrome	0.000736	0.00775	CcSEcCtD
Ketamine—Anorexia—Nelfinavir—acquired immunodeficiency syndrome	0.000732	0.00771	CcSEcCtD
Ketamine—Anorexia—Stavudine—acquired immunodeficiency syndrome	0.00073	0.00769	CcSEcCtD
Ketamine—Anorexia—Abacavir—acquired immunodeficiency syndrome	0.000719	0.00757	CcSEcCtD
Ketamine—Erythema—Efavirenz—acquired immunodeficiency syndrome	0.000717	0.00755	CcSEcCtD
Ketamine—Vision blurred—Indinavir—acquired immunodeficiency syndrome	0.000715	0.00753	CcSEcCtD
Ketamine—Convulsion—Zidovudine—acquired immunodeficiency syndrome	0.000707	0.00744	CcSEcCtD
Ketamine—GRIN2A—brain—acquired immunodeficiency syndrome	0.000706	0.00781	CbGeAlD
Ketamine—Hypotension—Abacavir—acquired immunodeficiency syndrome	0.000705	0.00742	CcSEcCtD
Ketamine—OPRM1—blood—acquired immunodeficiency syndrome	0.000692	0.00765	CbGeAlD
Ketamine—DRD2—retina—acquired immunodeficiency syndrome	0.00069	0.00763	CbGeAlD
Ketamine—Decreased appetite—Nevirapine—acquired immunodeficiency syndrome	0.00069	0.00726	CcSEcCtD
Ketamine—Erythema—Delavirdine—acquired immunodeficiency syndrome	0.000686	0.00722	CcSEcCtD
Ketamine—Pain—Nevirapine—acquired immunodeficiency syndrome	0.000678	0.00714	CcSEcCtD
Ketamine—Vision blurred—Efavirenz—acquired immunodeficiency syndrome	0.000676	0.00711	CcSEcCtD
Ketamine—Decreased appetite—Nelfinavir—acquired immunodeficiency syndrome	0.000668	0.00703	CcSEcCtD
Ketamine—OPRM1—spinal cord—acquired immunodeficiency syndrome	0.000667	0.00737	CbGeAlD
Ketamine—Decreased appetite—Stavudine—acquired immunodeficiency syndrome	0.000666	0.00701	CcSEcCtD
Ketamine—Anaphylactic shock—Zidovudine—acquired immunodeficiency syndrome	0.000666	0.00701	CcSEcCtD
Ketamine—Pain—Nelfinavir—acquired immunodeficiency syndrome	0.000657	0.00692	CcSEcCtD
Ketamine—Decreased appetite—Abacavir—acquired immunodeficiency syndrome	0.000656	0.00691	CcSEcCtD
Ketamine—Pain—Stavudine—acquired immunodeficiency syndrome	0.000655	0.0069	CcSEcCtD
Ketamine—Shock—Zidovudine—acquired immunodeficiency syndrome	0.000655	0.0069	CcSEcCtD
Ketamine—Vision blurred—Delavirdine—acquired immunodeficiency syndrome	0.000646	0.00681	CcSEcCtD
Ketamine—Pain—Abacavir—acquired immunodeficiency syndrome	0.000645	0.00679	CcSEcCtD
Ketamine—Anorexia—Zidovudine—acquired immunodeficiency syndrome	0.000635	0.00668	CcSEcCtD
Ketamine—OPRD1—brain—acquired immunodeficiency syndrome	0.000629	0.00696	CbGeAlD
Ketamine—Convulsion—Efavirenz—acquired immunodeficiency syndrome	0.000621	0.00654	CcSEcCtD
Ketamine—Anaphylactic shock—Indinavir—acquired immunodeficiency syndrome	0.000619	0.00652	CcSEcCtD
Ketamine—Vomiting—Amprenavir—acquired immunodeficiency syndrome	0.000615	0.00648	CcSEcCtD
Ketamine—Erythema—Saquinavir—acquired immunodeficiency syndrome	0.00061	0.00643	CcSEcCtD
Ketamine—Rash—Amprenavir—acquired immunodeficiency syndrome	0.00061	0.00643	CcSEcCtD
Ketamine—Dermatitis—Amprenavir—acquired immunodeficiency syndrome	0.00061	0.00642	CcSEcCtD
Ketamine—Shock—Indinavir—acquired immunodeficiency syndrome	0.000609	0.00641	CcSEcCtD
Ketamine—OPRK1—brain—acquired immunodeficiency syndrome	0.000604	0.00667	CbGeAlD
Ketamine—Vision blurred—Ritonavir—acquired immunodeficiency syndrome	0.000598	0.00629	CcSEcCtD
Ketamine—Anorexia—Indinavir—acquired immunodeficiency syndrome	0.00059	0.00621	CcSEcCtD
Ketamine—Erythema—Lamivudine—acquired immunodeficiency syndrome	0.000582	0.00613	CcSEcCtD
Ketamine—Decreased appetite—Zidovudine—acquired immunodeficiency syndrome	0.000579	0.00609	CcSEcCtD
Ketamine—Shock—Efavirenz—acquired immunodeficiency syndrome	0.000576	0.00606	CcSEcCtD
Ketamine—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.000575	0.00605	CcSEcCtD
Ketamine—Pain—Zidovudine—acquired immunodeficiency syndrome	0.000569	0.00599	CcSEcCtD
Ketamine—OPRM1—nervous system—acquired immunodeficiency syndrome	0.000562	0.00621	CbGeAlD
Ketamine—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000561	0.00591	CcSEcCtD
Ketamine—Anorexia—Efavirenz—acquired immunodeficiency syndrome	0.000558	0.00587	CcSEcCtD
Ketamine—Rash—Didanosine—acquired immunodeficiency syndrome	0.000556	0.00586	CcSEcCtD
Ketamine—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000556	0.00585	CcSEcCtD
Ketamine—Shock—Delavirdine—acquired immunodeficiency syndrome	0.000551	0.0058	CcSEcCtD
Ketamine—Convulsion—Ritonavir—acquired immunodeficiency syndrome	0.000549	0.00579	CcSEcCtD
Ketamine—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.000545	0.00602	CbGeAlD
Ketamine—OPRM1—central nervous system—acquired immunodeficiency syndrome	0.000541	0.00598	CbGeAlD
Ketamine—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.000538	0.00567	CcSEcCtD
Ketamine—Anorexia—Delavirdine—acquired immunodeficiency syndrome	0.000534	0.00562	CcSEcCtD
Ketamine—Pain—Indinavir—acquired immunodeficiency syndrome	0.000529	0.00558	CcSEcCtD
Ketamine—Convulsion—Saquinavir—acquired immunodeficiency syndrome	0.000529	0.00557	CcSEcCtD
Ketamine—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000524	0.00552	CcSEcCtD
Ketamine—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.000523	0.00551	CcSEcCtD
Ketamine—Shock—Ritonavir—acquired immunodeficiency syndrome	0.000509	0.00536	CcSEcCtD
Ketamine—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.000509	0.00535	CcSEcCtD
Ketamine—Convulsion—Lamivudine—acquired immunodeficiency syndrome	0.000505	0.00531	CcSEcCtD
Ketamine—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000504	0.00531	CcSEcCtD
Ketamine—Pain—Efavirenz—acquired immunodeficiency syndrome	0.0005	0.00527	CcSEcCtD
Ketamine—Rash—Nevirapine—acquired immunodeficiency syndrome	0.0005	0.00527	CcSEcCtD
Ketamine—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.0005	0.00526	CcSEcCtD
Ketamine—Anorexia—Ritonavir—acquired immunodeficiency syndrome	0.000493	0.0052	CcSEcCtD
Ketamine—Shock—Saquinavir—acquired immunodeficiency syndrome	0.00049	0.00516	CcSEcCtD
Ketamine—CYP2B6—skin of body—acquired immunodeficiency syndrome	0.00049	0.00542	CbGeAlD
Ketamine—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000489	0.00514	CcSEcCtD
Ketamine—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000487	0.00513	CcSEcCtD
Ketamine—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	0.000487	0.00512	CcSEcCtD
Ketamine—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000484	0.0051	CcSEcCtD
Ketamine—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000484	0.0051	CcSEcCtD
Ketamine—Hypotension—Ritonavir—acquired immunodeficiency syndrome	0.000484	0.00509	CcSEcCtD
Ketamine—Rash—Stavudine—acquired immunodeficiency syndrome	0.000483	0.00509	CcSEcCtD
Ketamine—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000483	0.00508	CcSEcCtD
Ketamine—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.00048	0.00505	CcSEcCtD
Ketamine—Pain—Delavirdine—acquired immunodeficiency syndrome	0.000479	0.00504	CcSEcCtD
Ketamine—Rash—Abacavir—acquired immunodeficiency syndrome	0.000476	0.00501	CcSEcCtD
Ketamine—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000475	0.00501	CcSEcCtD
Ketamine—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	0.000475	0.005	CcSEcCtD
Ketamine—Anorexia—Saquinavir—acquired immunodeficiency syndrome	0.000475	0.005	CcSEcCtD
Ketamine—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000471	0.00496	CcSEcCtD
Ketamine—Shock—Lamivudine—acquired immunodeficiency syndrome	0.000468	0.00492	CcSEcCtD
Ketamine—Hypotension—Saquinavir—acquired immunodeficiency syndrome	0.000466	0.0049	CcSEcCtD
Ketamine—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000456	0.00481	CcSEcCtD
Ketamine—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000455	0.00479	CcSEcCtD
Ketamine—Anorexia—Lamivudine—acquired immunodeficiency syndrome	0.000453	0.00477	CcSEcCtD
Ketamine—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	0.00045	0.00474	CcSEcCtD
Ketamine—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000448	0.00472	CcSEcCtD
Ketamine—SLC6A2—lung—acquired immunodeficiency syndrome	0.000444	0.00491	CbGeAlD
Ketamine—Hypotension—Lamivudine—acquired immunodeficiency syndrome	0.000444	0.00468	CcSEcCtD
Ketamine—PTGS1—skin of body—acquired immunodeficiency syndrome	0.000443	0.0049	CbGeAlD
Ketamine—Pain—Ritonavir—acquired immunodeficiency syndrome	0.000443	0.00466	CcSEcCtD
Ketamine—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	0.000433	0.00456	CcSEcCtD
Ketamine—OPRM1—brain—acquired immunodeficiency syndrome	0.000429	0.00475	CbGeAlD
Ketamine—Pain—Saquinavir—acquired immunodeficiency syndrome	0.000426	0.00449	CcSEcCtD
Ketamine—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000423	0.00446	CcSEcCtD
Ketamine—Rash—Zidovudine—acquired immunodeficiency syndrome	0.00042	0.00442	CcSEcCtD
Ketamine—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000419	0.00442	CcSEcCtD
Ketamine—CYP2C8—blood—acquired immunodeficiency syndrome	0.000416	0.0046	CbGeAlD
Ketamine—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	0.000413	0.00435	CcSEcCtD
Ketamine—SLC6A2—nervous system—acquired immunodeficiency syndrome	0.000411	0.00455	CbGeAlD
Ketamine—Pain—Lamivudine—acquired immunodeficiency syndrome	0.000406	0.00428	CcSEcCtD
Ketamine—DRD2—lung—acquired immunodeficiency syndrome	0.000405	0.00448	CbGeAlD
Ketamine—CYP2B6—lymphoid tissue—acquired immunodeficiency syndrome	0.000397	0.00439	CbGeAlD
Ketamine—SLC6A2—central nervous system—acquired immunodeficiency syndrome	0.000396	0.00438	CbGeAlD
Ketamine—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000395	0.00416	CcSEcCtD
Ketamine—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000394	0.00415	CcSEcCtD
Ketamine—CYP2B6—digestive system—acquired immunodeficiency syndrome	0.000392	0.00433	CbGeAlD
Ketamine—Rash—Indinavir—acquired immunodeficiency syndrome	0.00039	0.00411	CcSEcCtD
Ketamine—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.00039	0.00411	CcSEcCtD
Ketamine—CYP2C9—digestive system—acquired immunodeficiency syndrome	0.000388	0.00429	CbGeAlD
Ketamine—CYP2C8—vagina—acquired immunodeficiency syndrome	0.000386	0.00427	CbGeAlD
Ketamine—DRD2—nervous system—acquired immunodeficiency syndrome	0.000375	0.00414	CbGeAlD
Ketamine—CYP2B6—blood—acquired immunodeficiency syndrome	0.000373	0.00413	CbGeAlD
Ketamine—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000372	0.00392	CcSEcCtD
Ketamine—CYP2C9—blood—acquired immunodeficiency syndrome	0.00037	0.00409	CbGeAlD
Ketamine—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000369	0.00388	CcSEcCtD
Ketamine—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000368	0.00388	CcSEcCtD
Ketamine—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000368	0.00387	CcSEcCtD
Ketamine—DRD2—central nervous system—acquired immunodeficiency syndrome	0.000361	0.00399	CbGeAlD
Ketamine—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000356	0.00375	CcSEcCtD
Ketamine—PTGS1—digestive system—acquired immunodeficiency syndrome	0.000354	0.00392	CbGeAlD
Ketamine—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000353	0.00372	CcSEcCtD
Ketamine—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000353	0.00371	CcSEcCtD
Ketamine—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000347	0.00366	CcSEcCtD
Ketamine—CYP2B6—vagina—acquired immunodeficiency syndrome	0.000346	0.00383	CbGeAlD
Ketamine—PTGS1—blood—acquired immunodeficiency syndrome	0.000337	0.00373	CbGeAlD
Ketamine—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000332	0.0035	CcSEcCtD
Ketamine—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000329	0.00347	CcSEcCtD
Ketamine—CYP2B6—lung—acquired immunodeficiency syndrome	0.000327	0.00362	CbGeAlD
Ketamine—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000326	0.00344	CcSEcCtD
Ketamine—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000326	0.00343	CcSEcCtD
Ketamine—PTGS1—spinal cord—acquired immunodeficiency syndrome	0.000325	0.0036	CbGeAlD
Ketamine—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000317	0.00334	CcSEcCtD
Ketamine—SLC6A2—brain—acquired immunodeficiency syndrome	0.000314	0.00348	CbGeAlD
Ketamine—Rash—Saquinavir—acquired immunodeficiency syndrome	0.000314	0.00331	CcSEcCtD
Ketamine—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.000314	0.0033	CcSEcCtD
Ketamine—PTGS1—vagina—acquired immunodeficiency syndrome	0.000313	0.00346	CbGeAlD
Ketamine—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000307	0.00324	CcSEcCtD
Ketamine—SLC6A2—lymph node—acquired immunodeficiency syndrome	0.000304	0.00336	CbGeAlD
Ketamine—CYP2B6—nervous system—acquired immunodeficiency syndrome	0.000303	0.00335	CbGeAlD
Ketamine—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000302	0.00318	CcSEcCtD
Ketamine—Rash—Lamivudine—acquired immunodeficiency syndrome	0.0003	0.00316	CcSEcCtD
Ketamine—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000299	0.00315	CcSEcCtD
Ketamine—ABCB1—retina—acquired immunodeficiency syndrome	0.000298	0.0033	CbGeAlD
Ketamine—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000296	0.00312	CcSEcCtD
Ketamine—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000296	0.00327	CbGeAlD
Ketamine—PTGS1—lung—acquired immunodeficiency syndrome	0.000296	0.00327	CbGeAlD
Ketamine—CYP2B6—central nervous system—acquired immunodeficiency syndrome	0.000292	0.00323	CbGeAlD
Ketamine—DRD2—brain—acquired immunodeficiency syndrome	0.000286	0.00317	CbGeAlD
Ketamine—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000282	0.00297	CcSEcCtD
Ketamine—CYP3A4—blood—acquired immunodeficiency syndrome	0.000282	0.00312	CbGeAlD
Ketamine—PTGS1—nervous system—acquired immunodeficiency syndrome	0.000274	0.00303	CbGeAlD
Ketamine—PTGS1—central nervous system—acquired immunodeficiency syndrome	0.000264	0.00292	CbGeAlD
Ketamine—CYP2C8—brain—acquired immunodeficiency syndrome	0.000258	0.00286	CbGeAlD
Ketamine—CYP2B6—brain—acquired immunodeficiency syndrome	0.000232	0.00256	CbGeAlD
Ketamine—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000229	0.00253	CbGeAlD
Ketamine—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.00022	0.00244	CbGeAlD
Ketamine—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	0.000212	0.00234	CbGeAlD
Ketamine—ABCB1—digestive system—acquired immunodeficiency syndrome	0.000209	0.00232	CbGeAlD
Ketamine—PTGS1—brain—acquired immunodeficiency syndrome	0.000209	0.00232	CbGeAlD
Ketamine—PTGS1—lymph node—acquired immunodeficiency syndrome	0.000202	0.00224	CbGeAlD
Ketamine—ABCB1—blood—acquired immunodeficiency syndrome	0.0002	0.00221	CbGeAlD
Ketamine—ABCB1—bone marrow—acquired immunodeficiency syndrome	0.000193	0.00214	CbGeAlD
Ketamine—ABCB1—spinal cord—acquired immunodeficiency syndrome	0.000192	0.00213	CbGeAlD
Ketamine—ABCB1—vagina—acquired immunodeficiency syndrome	0.000185	0.00205	CbGeAlD
Ketamine—ABCB1—lung—acquired immunodeficiency syndrome	0.000175	0.00193	CbGeAlD
Ketamine—ABCB1—nervous system—acquired immunodeficiency syndrome	0.000162	0.00179	CbGeAlD
Ketamine—ABCB1—central nervous system—acquired immunodeficiency syndrome	0.000156	0.00172	CbGeAlD
Ketamine—ABCB1—brain—acquired immunodeficiency syndrome	0.000124	0.00137	CbGeAlD
Ketamine—ABCB1—lymph node—acquired immunodeficiency syndrome	0.00012	0.00132	CbGeAlD
Ketamine—TACR1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	9.75e-05	0.00174	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	9.75e-05	0.00174	CbGpPWpGaD
Ketamine—ABCB1—Allograft Rejection—IL4—acquired immunodeficiency syndrome	9.64e-05	0.00172	CbGpPWpGaD
Ketamine—GRIN1—Spinal Cord Injury—TNF—acquired immunodeficiency syndrome	9.63e-05	0.00172	CbGpPWpGaD
Ketamine—TACR1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	9.55e-05	0.0017	CbGpPWpGaD
Ketamine—TACR1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	9.55e-05	0.0017	CbGpPWpGaD
Ketamine—OPRD1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	9.52e-05	0.0017	CbGpPWpGaD
Ketamine—OPRD1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	9.52e-05	0.0017	CbGpPWpGaD
Ketamine—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	9.51e-05	0.0017	CbGpPWpGaD
Ketamine—PTGS1—Selenium Micronutrient Network—IFNG—acquired immunodeficiency syndrome	9.5e-05	0.00169	CbGpPWpGaD
Ketamine—OPRM1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	9.47e-05	0.00169	CbGpPWpGaD
Ketamine—OPRK1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	9.45e-05	0.00168	CbGpPWpGaD
Ketamine—ABCB1—Allograft Rejection—HLA-B—acquired immunodeficiency syndrome	9.43e-05	0.00168	CbGpPWpGaD
Ketamine—DRD2—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	9.39e-05	0.00167	CbGpPWpGaD
Ketamine—OPRD1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	9.3e-05	0.00166	CbGpPWpGaD
Ketamine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	9.26e-05	0.00165	CbGpPWpGaD
Ketamine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	9.26e-05	0.00165	CbGpPWpGaD
Ketamine—TACR1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	9.23e-05	0.00164	CbGpPWpGaD
Ketamine—DRD2—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	9.21e-05	0.00164	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	9.07e-05	0.00162	CbGpPWpGaD
Ketamine—TACR1—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	9.02e-05	0.00161	CbGpPWpGaD
Ketamine—OPRK1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	8.88e-05	0.00158	CbGpPWpGaD
Ketamine—OPRM1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	8.86e-05	0.00158	CbGpPWpGaD
Ketamine—DRD2—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	8.83e-05	0.00157	CbGpPWpGaD
Ketamine—DRD2—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	8.83e-05	0.00157	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	8.82e-05	0.00157	CbGpPWpGaD
Ketamine—OPRK1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	8.77e-05	0.00156	CbGpPWpGaD
Ketamine—DRD2—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	8.72e-05	0.00155	CbGpPWpGaD
Ketamine—TACR1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	8.67e-05	0.00155	CbGpPWpGaD
Ketamine—TACR1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	8.67e-05	0.00155	CbGpPWpGaD
Ketamine—DRD2—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	8.62e-05	0.00154	CbGpPWpGaD
Ketamine—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	8.57e-05	0.00153	CbGpPWpGaD
Ketamine—OPRD1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	8.41e-05	0.0015	CbGpPWpGaD
Ketamine—OPRK1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	8.35e-05	0.00149	CbGpPWpGaD
Ketamine—OPRK1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	8.35e-05	0.00149	CbGpPWpGaD
Ketamine—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	8.34e-05	0.00149	CbGpPWpGaD
Ketamine—OPRM1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	8.3e-05	0.00148	CbGpPWpGaD
Ketamine—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	8.26e-05	0.00147	CbGpPWpGaD
Ketamine—DRD2—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	8.2e-05	0.00146	CbGpPWpGaD
Ketamine—OPRK1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	8.16e-05	0.00145	CbGpPWpGaD
Ketamine—OPRM1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	7.99e-05	0.00142	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	7.95e-05	0.00142	CbGpPWpGaD
Ketamine—GRIN1—Spinal Cord Injury—IL6—acquired immunodeficiency syndrome	7.77e-05	0.00139	CbGpPWpGaD
Ketamine—GRIN1—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	7.71e-05	0.00137	CbGpPWpGaD
Ketamine—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	7.51e-05	0.00134	CbGpPWpGaD
Ketamine—OPRM1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	7.5e-05	0.00134	CbGpPWpGaD
Ketamine—DRD2—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	7.47e-05	0.00133	CbGpPWpGaD
Ketamine—OPRM1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	7.41e-05	0.00132	CbGpPWpGaD
Ketamine—OPRK1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	7.38e-05	0.00131	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	7.36e-05	0.00131	CbGpPWpGaD
Ketamine—TACR1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	7.27e-05	0.0013	CbGpPWpGaD
Ketamine—OPRD1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	7.24e-05	0.00129	CbGpPWpGaD
Ketamine—TACR1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	7.16e-05	0.00128	CbGpPWpGaD
Ketamine—OPRM1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	7.06e-05	0.00126	CbGpPWpGaD
Ketamine—OPRM1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	7.06e-05	0.00126	CbGpPWpGaD
Ketamine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	7.05e-05	0.00126	CbGpPWpGaD
Ketamine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	7.02e-05	0.00125	CbGpPWpGaD
Ketamine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	7.02e-05	0.00125	CbGpPWpGaD
Ketamine—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	6.98e-05	0.00124	CbGpPWpGaD
Ketamine—OPRM1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	6.89e-05	0.00123	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	6.72e-05	0.0012	CbGpPWpGaD
Ketamine—DRD2—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	6.72e-05	0.0012	CbGpPWpGaD
Ketamine—TACR1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	6.6e-05	0.00118	CbGpPWpGaD
Ketamine—TACR1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	6.55e-05	0.00117	CbGpPWpGaD
Ketamine—OPRD1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	6.52e-05	0.00116	CbGpPWpGaD
Ketamine—TACR1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	6.5e-05	0.00116	CbGpPWpGaD
Ketamine—OPRK1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	6.35e-05	0.00113	CbGpPWpGaD
Ketamine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	6.35e-05	0.00113	CbGpPWpGaD
Ketamine—DRD2—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	6.29e-05	0.00112	CbGpPWpGaD
Ketamine—OPRM1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	6.23e-05	0.00111	CbGpPWpGaD
Ketamine—GRIN1—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	6.22e-05	0.00111	CbGpPWpGaD
Ketamine—PTGS1—Selenium Micronutrient Network—TNF—acquired immunodeficiency syndrome	6.15e-05	0.0011	CbGpPWpGaD
Ketamine—DRD2—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	6.05e-05	0.00108	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	6.03e-05	0.00107	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	5.99e-05	0.00107	CbGpPWpGaD
Ketamine—PTGS1—Metabolism—TAT—acquired immunodeficiency syndrome	5.97e-05	0.00106	CbGpPWpGaD
Ketamine—TACR1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	5.95e-05	0.00106	CbGpPWpGaD
Ketamine—OPRM1—TCR Signaling Pathway—IL6—acquired immunodeficiency syndrome	5.85e-05	0.00104	CbGpPWpGaD
Ketamine—ABCB1—Allograft Rejection—IFNG—acquired immunodeficiency syndrome	5.83e-05	0.00104	CbGpPWpGaD
Ketamine—OPRD1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	5.75e-05	0.00102	CbGpPWpGaD
Ketamine—OPRD1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	5.72e-05	0.00102	CbGpPWpGaD
Ketamine—OPRK1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	5.72e-05	0.00102	CbGpPWpGaD
Ketamine—DRD2—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	5.69e-05	0.00101	CbGpPWpGaD
Ketamine—DRD2—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	5.62e-05	0.001	CbGpPWpGaD
Ketamine—SLC6A2—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	5.59e-05	0.000997	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	5.49e-05	0.000979	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	5.49e-05	0.000979	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	5.45e-05	0.000971	CbGpPWpGaD
Ketamine—OPRD1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	5.38e-05	0.000959	CbGpPWpGaD
Ketamine—OPRD1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	5.38e-05	0.000959	CbGpPWpGaD
Ketamine—OPRM1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	5.37e-05	0.000957	CbGpPWpGaD
Ketamine—DRD2—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	5.35e-05	0.000953	CbGpPWpGaD
Ketamine—DRD2—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	5.35e-05	0.000953	CbGpPWpGaD
Ketamine—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	5.34e-05	0.000952	CbGpPWpGaD
Ketamine—DRD2—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	5.22e-05	0.000931	CbGpPWpGaD
Ketamine—OPRD1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	5.2e-05	0.000926	CbGpPWpGaD
Ketamine—ABCB1—Allograft Rejection—IL2—acquired immunodeficiency syndrome	5.18e-05	0.000923	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	5.12e-05	0.000913	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	5.12e-05	0.000913	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	5.09e-05	0.000908	CbGpPWpGaD
Ketamine—PTGS1—Metabolism—AGPS—acquired immunodeficiency syndrome	5.08e-05	0.000905	CbGpPWpGaD
Ketamine—OPRK1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	5.04e-05	0.000898	CbGpPWpGaD
Ketamine—OPRK1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	5.02e-05	0.000894	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.97e-05	0.000886	CbGpPWpGaD
Ketamine—PTGS1—Selenium Micronutrient Network—IL6—acquired immunodeficiency syndrome	4.96e-05	0.000884	CbGpPWpGaD
Ketamine—OPRD1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	4.89e-05	0.000871	CbGpPWpGaD
Ketamine—OPRD1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	4.89e-05	0.000871	CbGpPWpGaD
Ketamine—OPRM1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	4.84e-05	0.000862	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	4.82e-05	0.000859	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	4.82e-05	0.000859	CbGpPWpGaD
Ketamine—DRD2—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	4.81e-05	0.000858	CbGpPWpGaD
Ketamine—DRD2—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	4.72e-05	0.000842	CbGpPWpGaD
Ketamine—OPRK1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	4.72e-05	0.000841	CbGpPWpGaD
Ketamine—OPRK1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	4.72e-05	0.000841	CbGpPWpGaD
Ketamine—OPRK1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	4.56e-05	0.000812	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—TAT—acquired immunodeficiency syndrome	4.56e-05	0.000812	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.36e-05	0.000777	CbGpPWpGaD
Ketamine—OPRK1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	4.28e-05	0.000764	CbGpPWpGaD
Ketamine—OPRK1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	4.28e-05	0.000764	CbGpPWpGaD
Ketamine—OPRM1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	4.26e-05	0.000759	CbGpPWpGaD
Ketamine—OPRM1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	4.24e-05	0.000756	CbGpPWpGaD
Ketamine—OPRD1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	4.09e-05	0.00073	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	4.07e-05	0.000726	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	4.07e-05	0.000726	CbGpPWpGaD
Ketamine—DRD2—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	4.07e-05	0.000725	CbGpPWpGaD
Ketamine—OPRD1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	4.03e-05	0.000719	CbGpPWpGaD
Ketamine—OPRM1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	3.99e-05	0.000711	CbGpPWpGaD
Ketamine—OPRM1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	3.99e-05	0.000711	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.9e-05	0.000695	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—AGPS—acquired immunodeficiency syndrome	3.87e-05	0.000691	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—TAT—acquired immunodeficiency syndrome	3.86e-05	0.000688	CbGpPWpGaD
Ketamine—OPRM1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.85e-05	0.000686	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.84e-05	0.000684	CbGpPWpGaD
Ketamine—TACR1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.78e-05	0.000674	CbGpPWpGaD
Ketamine—ABCB1—Allograft Rejection—TNF—acquired immunodeficiency syndrome	3.77e-05	0.000672	CbGpPWpGaD
Ketamine—OPRD1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.72e-05	0.000662	CbGpPWpGaD
Ketamine—OPRD1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.69e-05	0.000657	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.68e-05	0.000656	CbGpPWpGaD
Ketamine—DRD2—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	3.66e-05	0.000653	CbGpPWpGaD
Ketamine—OPRD1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.66e-05	0.000653	CbGpPWpGaD
Ketamine—OPRM1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.62e-05	0.000645	CbGpPWpGaD
Ketamine—OPRM1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.62e-05	0.000645	CbGpPWpGaD
Ketamine—OPRK1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.59e-05	0.00064	CbGpPWpGaD
Ketamine—OPRK1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.54e-05	0.00063	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.51e-05	0.000626	CbGpPWpGaD
Ketamine—GRIN1—Axon guidance—IL6—acquired immunodeficiency syndrome	3.47e-05	0.000618	CbGpPWpGaD
Ketamine—TACR1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.43e-05	0.000612	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.39e-05	0.000605	CbGpPWpGaD
Ketamine—GRIN2B—Axon guidance—IL6—acquired immunodeficiency syndrome	3.38e-05	0.000602	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—TAT—acquired immunodeficiency syndrome	3.36e-05	0.000599	CbGpPWpGaD
Ketamine—OPRD1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.35e-05	0.000597	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—AGPS—acquired immunodeficiency syndrome	3.28e-05	0.000585	CbGpPWpGaD
Ketamine—OPRK1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.26e-05	0.000581	CbGpPWpGaD
Ketamine—OPRK1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.23e-05	0.000576	CbGpPWpGaD
Ketamine—DRD2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	3.23e-05	0.000575	CbGpPWpGaD
Ketamine—DRD2—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	3.21e-05	0.000573	CbGpPWpGaD
Ketamine—OPRK1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.21e-05	0.000572	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—TAT—acquired immunodeficiency syndrome	3.14e-05	0.00056	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.09e-05	0.00055	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.09e-05	0.00055	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.07e-05	0.000547	CbGpPWpGaD
Ketamine—GRIN1—Developmental Biology—TNF—acquired immunodeficiency syndrome	3.06e-05	0.000546	CbGpPWpGaD
Ketamine—OPRM1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.03e-05	0.000541	CbGpPWpGaD
Ketamine—DRD2—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	3.02e-05	0.000539	CbGpPWpGaD
Ketamine—DRD2—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	3.02e-05	0.000539	CbGpPWpGaD
Ketamine—OPRM1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.99e-05	0.000533	CbGpPWpGaD
Ketamine—GRIN2B—Developmental Biology—TNF—acquired immunodeficiency syndrome	2.99e-05	0.000532	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.98e-05	0.00053	CbGpPWpGaD
Ketamine—OPRK1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.94e-05	0.000523	CbGpPWpGaD
Ketamine—DRD2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	2.92e-05	0.00052	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.89e-05	0.000514	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.89e-05	0.000514	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—AGPS—acquired immunodeficiency syndrome	2.86e-05	0.000509	CbGpPWpGaD
Ketamine—SLC6A2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	2.84e-05	0.000506	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.79e-05	0.000497	CbGpPWpGaD
Ketamine—OPRM1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.75e-05	0.000491	CbGpPWpGaD
Ketamine—DRD2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	2.74e-05	0.000489	CbGpPWpGaD
Ketamine—DRD2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	2.74e-05	0.000489	CbGpPWpGaD
Ketamine—OPRM1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.73e-05	0.000487	CbGpPWpGaD
Ketamine—OPRM1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.71e-05	0.000484	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.69e-05	0.00048	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—AGPS—acquired immunodeficiency syndrome	2.67e-05	0.000476	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.53e-05	0.000451	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.53e-05	0.000451	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.52e-05	0.000448	CbGpPWpGaD
Ketamine—OPRM1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.48e-05	0.000442	CbGpPWpGaD
Ketamine—GRIN1—Developmental Biology—IL6—acquired immunodeficiency syndrome	2.47e-05	0.000441	CbGpPWpGaD
Ketamine—GRIN2B—Developmental Biology—IL6—acquired immunodeficiency syndrome	2.41e-05	0.00043	CbGpPWpGaD
Ketamine—PTGS1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	2.34e-05	0.000417	CbGpPWpGaD
Ketamine—DRD2—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	2.33e-05	0.000415	CbGpPWpGaD
Ketamine—DRD2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.3e-05	0.00041	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.27e-05	0.000405	CbGpPWpGaD
Ketamine—DRD2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.26e-05	0.000404	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.2e-05	0.000391	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.16e-05	0.000385	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.14e-05	0.000381	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.14e-05	0.000381	CbGpPWpGaD
Ketamine—OPRD1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.13e-05	0.00038	CbGpPWpGaD
Ketamine—DRD2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.09e-05	0.000372	CbGpPWpGaD
Ketamine—DRD2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.07e-05	0.000369	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	2.07e-05	0.000369	CbGpPWpGaD
Ketamine—DRD2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.06e-05	0.000366	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.03e-05	0.000362	CbGpPWpGaD
Ketamine—TACR1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.02e-05	0.00036	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.98e-05	0.000353	CbGpPWpGaD
Ketamine—OPRD1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.93e-05	0.000345	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.93e-05	0.000343	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.91e-05	0.00034	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.9e-05	0.000338	CbGpPWpGaD
Ketamine—DRD2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.88e-05	0.000335	CbGpPWpGaD
Ketamine—OPRK1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.87e-05	0.000333	CbGpPWpGaD
Ketamine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	1.86e-05	0.000332	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	1.76e-05	0.000314	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.73e-05	0.000309	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.72e-05	0.000307	CbGpPWpGaD
Ketamine—OPRK1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.7e-05	0.000302	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.63e-05	0.00029	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.62e-05	0.000289	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.62e-05	0.000289	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.6e-05	0.000286	CbGpPWpGaD
Ketamine—OPRM1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.58e-05	0.000281	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.51e-05	0.000269	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.47e-05	0.000261	CbGpPWpGaD
Ketamine—OPRM1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.43e-05	0.000256	CbGpPWpGaD
Ketamine—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.25e-05	0.000223	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.23e-05	0.00022	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.23e-05	0.000219	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.21e-05	0.000216	CbGpPWpGaD
Ketamine—DRD2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.2e-05	0.000213	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.19e-05	0.000213	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.14e-05	0.000204	CbGpPWpGaD
Ketamine—OPRD1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.14e-05	0.000203	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.11e-05	0.000198	CbGpPWpGaD
Ketamine—DRD2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.09e-05	0.000194	CbGpPWpGaD
Ketamine—PTGS1—Metabolism—ALB—acquired immunodeficiency syndrome	1.04e-05	0.000186	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1e-05	0.000179	CbGpPWpGaD
Ketamine—OPRK1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	9.97e-06	0.000178	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	8.47e-06	0.000151	CbGpPWpGaD
Ketamine—OPRM1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	8.43e-06	0.00015	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—ALB—acquired immunodeficiency syndrome	7.95e-06	0.000142	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—ALB—acquired immunodeficiency syndrome	6.73e-06	0.00012	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.72e-06	0.00012	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.42e-06	0.000114	CbGpPWpGaD
Ketamine—DRD2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	6.39e-06	0.000114	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.89e-06	0.000105	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	5.86e-06	0.000104	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—ALB—acquired immunodeficiency syndrome	5.47e-06	9.76e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.98e-06	8.87e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.77e-06	6.72e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	3.61e-06	6.44e-05	CbGpPWpGaD
